6th edition, 2010. | Published in collaboration with World Health Organisation and Clinton Health Access Initiative.
Antimicrobial Resistance Surveillance and Research Network | This document contains detail procedures on sample collection, transport, isolation, identification of fungi for the diagnosis of invasive fungal infections and antifungal susceptibility testing of yeast
Funded by CBM: www.cbm.org
Psychiatry and Pediatrics
Chapter I.5
NEMLIST | Sixth Edition | February 2016
Funded by CBM: www.cbm.org
(Health Systems in Transition, Vol. 4, No. 3, 2014)
UNICEF provides a detailed update and list of Ebola virus disease personal protective equipment technical specifications for use in high- and low-risk settings. It includes barriers for full body protection, as well as the head, nose, mouth, eyes, hands and feet. In selecting the right PPE specifica...tions for frontline workers, the degree of contact with infectious material, and the potential for infected fluid penetration should be considered.
more
These guidelines for the National Pharmacovigilance and Medicine Information System in Rwanda have been developed to ensure that safe, efficacious and quality medicines are made available to all Rwandans.
A guide for Regional Workshop and Hospital Technicians
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more